FAQ Library

FAQ Library published on August 18, 2022
Dr. Richter describes why personalized medicine is the future of myeloma treatment.
FAQ Library published on August 16, 2022
Join Dr. Richter as he explains the biggest study from EHA and ASCO 2022 and what it means for patients who are transplant eligible.
FAQ Library published on August 11, 2022
In this activity, Dr. Richter describes what the current challenges are when managing patients with multiple myeloma.
FAQ Library published on April 11, 2022
Join Dr. Usmani as he describes how clinicians should monitor patients after their first or second dose after switching from IV daratumumab to subcutaneous.
FAQ Library published on April 6, 2022
Dr. Lonial discusses the impact of safety and efficacy in four-drug regimens compared to the three-drug regimens for frontline therapy.
FAQ Library published on March 25, 2021
In this activity, Dr. Baljevic discusses the side-effect profile associated with four-drug regimens.
FAQ Library published on March 23, 2021
In this activity, Dr. Baljevic explains the NCCN guidelines outlining four-drug combinations listed for use in newly diagnosed transplant-eligible patients.
FAQ Library published on January 20, 2021
In this activity, Dr. Raje provides a summary of the KarMMa trial and BB2121 in relapsed/refractory multiple myeloma.
FAQ Library published on January 14, 2021
Dr. Raje explains therapeutic interventions for smoldering multiple myeloma, as well as how to better risk-stratify patients.
FAQ Library published on January 12, 2021
In this activity, Dr. Noopur Raje discusses how to risk-stratify patients with smoldering myeloma and the updated definition of symptomatic myeloma.
Page 1 of 2
Results 1 - 10 of 11